Investigation announced for Long-Term Investors in Moderna, Inc. (NASDAQ: MRNA) shares

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Moderna, Inc.

Investors who purchased shares of Moderna, Inc. (NASDAQ: MRNA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Moderna directors breached their fiduciary duties and caused damage to the company and its shareholders.

Cambridge, MA based Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.

On May 18, 2020, Moderna, Inc a announced Phase 1 trial results for a candidate vaccine for COVID-19 under development by the Company, indicating that the candidate appeared to generate an immune response similar to the response seen in individuals who have been infected by the virus and recovered. Specifically, Moderna reported that eight patients who received two doses of the vaccine at the lowest and middle doses tested - 25 and 100 micrograms - developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection.

Shares of Moderna, Inc. (NASDAQ: MRNA) rose to $87.00 per share on May 18, 2020.

In the days following Moderna’s announcement, the Company’s announcement was the subject of skeptical commentary from multiple sources. For example, on May 19, 2020, an article was published entitled "Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine," which noted, in part, that "[w]hile Moderna blitzed the media, it revealed very little information - and most of what it did disclose were words, not data."

Shares of Moderna, Inc. (NASDAQ: MRNA) declined to $57.05 per share on May 26, 2020.

Those who purchased shares of Moderna, Inc. (NASDAQ: MRNA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.